Dyadic Intl Inc Del Stock Price, News & Analysis

Dyadic International (NASDAQ: DYAI), a biotechnology company specializing in large-scale protein manufacturing for vaccines, therapeutics, and industrial applications, has scheduled its Q1 2025 financial results announcement and corporate update conference call for Wednesday, May 14, 2025, at 5:00 PM ET.

Shareholders and interested parties can access the call through toll-free (+1-877-407-0784) or international (+1-201-689-8560) numbers using Conference ID 13751387. A webcast will be available, with an archive accessible within 24 hours on Dyadic's Investor Relations website.

Dyadic International (Nasdaq: DYAI) has announced its participation in the 2025 World Vaccine Congress in Washington, D.C. CEO Mark Emalfarb will present on April 23, 2025, focusing on the company's C1 Platform and its application in addressing avian influenza (H5N1) and future pandemics.

The presentation, scheduled for 12:40 PM-1:10 PM in Room 202A, will showcase recent preclinical research utilizing Dyadic's proprietary C1 expression platform. The company will highlight data related to the production of non-mRNA antigens and reagents for vaccine production, demonstrating the platform's ability to elicit high neutralizing antibodies.

The C1 platform aims to enable rapid, cost-effective production of antigens, reagents, and cell culture media products to address global health challenges through scalable biomanufacturing. Interested parties can meet the management team at booth #654 or schedule meetings via assistant@dyadic.com.

Dyadic International (NASDAQ: DYAI) reported its 2024 financial results, highlighting significant progress in commercializing its Dapibus™ and C1 microbial protein production platforms. The company achieved $1.9 million in milestone and license revenue and secured up to $7.5 million in grants from CEPI and Gates Foundation.

Key financial metrics include:

• Total revenue increased to $3.5 million (vs $2.9 million in 2023)
• Net loss decreased to $5.8 million or $(0.20) per share (vs $6.8 million in 2023)
• Cash position of $9.3 million as of December 31, 2024

Notable developments include advancing Human Serum Albumin toward commercial launch in Q2 2025, expanding alternative protein portfolio with six life science products, and progressing in animal and human health applications. The company is developing multiple products nearing market launch, including DNASe1 and various enzymes for non-animal dairy applications.

Dyadic International (NASDAQ: DYAI) has received a $4.5 million funding award from CEPI to accelerate protein-based vaccine development using their C1 filamentous fungus technology. The funding will be directed to Fondazione Biotecnopolo di Siena (FBS) for proof-of-concept research.

The project aims to demonstrate that C1 technology could reduce vaccine production time from the current 4-6 months to just 35 days, significantly accelerating Phase 1 trials. Unlike traditional mammalian cell production, C1 fungus can rapidly produce quality vaccine proteins without extensive testing requirements.

The research will compare SARS-CoV-2 spike protein production using both C1 fungus and mammalian cell approaches. If successful, the technology could enable faster, more cost-effective vaccine manufacturing, particularly beneficial for regions with less established infrastructure, supporting the G7 and G20's 100 Days Mission for pandemic response.

Dyadic International (Nasdaq: DYAI), a biotechnology company specializing in large-scale protein manufacturing for human and animal vaccines, therapeutics, and non-pharmaceutical applications, has announced its upcoming 2024 full-year financial results release and conference call.

The company will host the corporate update conference call on Wednesday, March 26, 2025, at 5:00 p.m. Eastern Time. Investors can access the call through toll-free (+1-877-407-0784) or international (+1-201-689-8560) numbers using Conference ID 13751386. A webcast will also be available, with an archive accessible within 24 hours on Dyadic's Investor Relations website.

Dyadic International (Nasdaq: DYAI), a biotechnology company specializing in large-scale protein manufacturing for vaccines, therapeutics, and industrial applications, has announced its participation in multiple industry events during March 2025.

The company will be present at three major events:

• The World AGRI-Tech Innovation Summit in San Francisco, CA (March 11-12, 2025)
• The Future Food-Tech event in San Francisco, CA (March 13-14, 2025), where they will be exhibiting at Booth No: #2
• The Microbial Engineering III conference in Porto, Portugal (March 30-April 3, 2025), focused on new generation cell factory developments

Interested parties can schedule meetings with Dyadic management by contacting assistant@dyadic.com.

Dyadic International (Nasdaq: DYAI) provided a business update highlighting developments in its Alternative Proteins business and C1 platform applications. The company will attend the 43rd Annual J.P. Morgan Healthcare Conference starting January 13, 2025.

Key developments include:

• Preparation for Human Serum Albumin launch in H1 2025 with Proliant Health, expecting a $500,000 milestone payment
• Development of recombinant transferrin for pharmaceutical cell culture media
• Launch preparation of a recombinant dairy enzyme for cheese production using Dapibus™ platform
• Progress in DNA-RNA enzyme products, including DNase 1
• Collaboration with ViroVax on H5N1 Avian Influenza and Mpox vaccines
• A $3 million grant from Bill & Melinda Gates Foundation for RSV and Malaria research

The company's C1-produced H5 Avian Influenza vaccine candidate has shown cross-protection against multiple H5 virus strains, with promising results in both poultry and cattle applications.

Dyadic International (NASDAQ: DYAI) has received a $3 million grant from the Gates Foundation to develop cost-effective monoclonal antibodies (mAbs) for RSV and malaria using its C1 platform technology. The initiative aims to provide affordable therapeutics for underserved populations, particularly in low-income and middle-income countries (LMICs). RSV causes 3.2-36 million hospitalizations and over 100,000 deaths annually, while malaria affected 249 million cases and caused 608,000 deaths globally in 2022. The C1 platform is designed to accelerate development, reduce production costs, and improve scalability of biologic vaccines and therapeutics. Dyadic plans to commercialize successful antibodies through licensure to expand access to affordable treatment options globally.